fexinidazole,
HOE 239,
Fexinidazole,
59729-37-2,
1-Methyl-2-((4-(methylthio)phenoxy)methyl)-5-nitro-1H-imidazole,
UNII-306ERL82IR,
Hoe-239,
306ERL82IR,
AK116408,
Fexinidazol,
Fexinidazolum,
1-methyl-2-[(4-methylsulfanylphenoxy)methyl]-5-nitroimidazole,
1-Methyl-2-((4-(methylthio)phenoxy)-methyl)-5-nitro-1H-imidazole,
fexinidazole[inn],
Fexinidazole [INN],
Fexinidazol [INN-Spanish],
Fexinidazolum [INN-Latin],
AC1L2AGG,
Fexinidazole (HOE-239),
MLS006010234,
SCHEMBL1163575,
ZINC1448,
CHEMBL1631694,
DTXSID00208448,
HOE 239,
MIWWSGDADVMLTG-UHFFFAOYSA-N,
AC1Q2092,
BCP07460,
KS-00001D7Z,
MFCD00866607,
AKOS016010427,
API0011451,
CS-5535,
DB12265,
MP-1536,
SB16940,
4CA-0532,
AJ-08031,
HY-13801,
SMR004701311,
AB0068694,
AX8130352,
ST24027121,
Z4922,
1-methyl-2-(4-methylthiophenyloxymethyl)-5-nitro-imidazole,
1-Methyl-2-((p-(methylthio)phenoxy)methyl)-5-nitroimidazole,
1-methyl-2-(4-methylthiophenyl-oxymethyl)-5-nitro-imidazole,
D00RWW,
C12H13N3O3S,
CID68792,
AR-1J0779,
C12-H13-N3-O3-S,
DS-4574,
Fexinidazole (human African trypanosomiasis),
Fexinidazole (HAT), Drugs for Neglected Diseases initiative,
Fexinidazole (African sleeping sickness), Drugs for Neglected Diseases initiative,
Fexinidazole (human African trypanosomiasis), Drugs for Neglected Diseases initiative,
6140-74-5,